Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were eligible to receive a COVID-19 vaccine.
- People who experienced at least one heart-related symptom within 42 days of a COVID-19 vaccine, such as chest pain, chest pressure or discomfort, shortness of breath or pain when breathing, a pounding or irregular heartbeat, heavy sweating, fainting, or sudden cardiac arrest.
- People who experienced at least two general (non-specific) symptoms within 42 days of a COVID-19 vaccine, such as fatigue, abdominal pain, dizziness or fainting, swelling, or cough.
- People with no symptoms but who have abnormal tissue test results, or a combination of abnormal heart blood test results and abnormal heart scan results (ultrasound or MRI).
- People who also have at least one of the following findings: elevated heart enzyme levels in blood tests (Troponin T, Troponin I, or CK-MB); an abnormal heart MRI; new or worsening irregular heart rhythms on a heart tracing or monitor; abnormal heart ultrasound findings; a specific sound or pulse finding detected during a physical exam; fluid around the heart or signs of inflammation seen on a scan, or elevated inflammation markers in blood tests; an enlarged heart seen on a chest X-ray; or evidence of heart muscle inflammation found during tissue examination (at autopsy or biopsy).
Who may not be able to join:
- People whose symptoms and findings are clearly explained by another condition unrelated to the vaccine, such as Lyme disease affecting the heart or an autoimmune heart condition.
- People whose symptoms began more than 42 days after receiving a COVID-19 vaccine.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peter Liu, MD, Ottawa Heart Institute Research Corporation
Phone: 6136967351
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients with autoimmune disease; Composite of MACE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.